Get the Stockscreener App
147.33
1.91%
-2.87
Guardant Health Inc stock is traded at $147.33, with a volume of 1.88M.
It is down -1.91% in the last 24 hours and up +7.57% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$150.20
Open:
$150.2
24h Volume:
1.88M
Relative Volume:
0.73
Market Cap:
$19.54B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-43.33
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
-5.48%
1M Performance:
+7.57%
6M Performance:
+28.39%
1Y Performance:
+223.87%
1-Day Range:
$145.49
$152.38
1-Week Range:
$144.85
$156.54
52-Week Range:
$40.35
$174.08
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
147.33 | 19.54B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health Stock: An Expensive Price For A Great Company (NASDAQ:GH) - Seeking Alpha
Guardant Health, Inc. (GH) stock price, news, quote and history - Yahoo Finance UK
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Form 4 Guardant Health Inc For: 22 July By Investing.com - Investing.com Nigeria
Temasek Holdings Private Ltd Sells 58,526 Shares of Guardant Health, Inc. $GH - MarketBeat
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Biomarker Collaboration and Licensing Deals Report 2016-2026Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More - Yahoo Finance
Strong Results Boosted Guardant Health (GH) in Q2 - Yahoo Finance
Guardant Health, Inc. $GH Stock Position Raised by WCM Investment Management LLC - MarketBeat
Amova Asset Management Americas Inc. Sells 156,738 Shares of Guardant Health, Inc. $GH - MarketBeat
EBITDA per share of Guardant Health, Inc. – LSX:A2N5RY - TradingView
Guardant Health Surges 53% on UnitedHealth Coverage Deal — "Single-Drop Blood Test for Cancer" Becomes Reality - finance.biggo.com
Guardant Health Falls as Recent Rally Appears to Cool - Quiver Quantitative
Lobbying Update: $180,000 of GUARDANT HEALTH lobbying was just disclosed - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: Unpacking a 48% Revenue Growth in the Diagnostics Sector - DirectorsTalk Interviews
Guardant Health, Inc. $GH Stock Position Raised by D.A. Davidson & CO. - MarketBeat
Responsive Playbooks and the GH Inflection - Stock Traders Daily
Future Fund LLC Increases Position in Guardant Health, Inc. $GH - MarketBeat
Fifth Third Bancorp Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Form 144 Guardant Health For: 16 July By Investing.com - Investing.com Nigeria
Guardant Health director Tariq Musa sells $18,941 in stock By Investing.com - Investing.com Nigeria
Form 4 Guardant Health Inc For: 16 July By Investing.com - Investing.com Nigeria
GH Maintains Rating by Guggenheim -- Price Target Raised to $190 - GuruFocus
Guardant Health director Tariq Musa sells $18,941 in stock - Investing.com
Musa Tariq plans sale of Guardant Health (NASDAQ: GH) common stock - Stock Titan
Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN) - Benzinga
Guggenheim raises Guardant Health stock price target on Shield data - Investing.com
Guggenheim raises Guardant Health stock price target on Shield data By Investing.com - Investing.com Canada
Guggenheim Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - MarketBeat
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen raises Guardant Health stock price target on FDA approval - Investing.com
How Expanded Coverage for Guardant’s Shield Test Will Impact UnitedHealth Group (UNH) Investors - simplywall.st
GH Maintained by Canaccord Genuity -- Price Target Raised to $20 - GuruFocus
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $205 - Moomoo
Guardant Health (GH) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $190 - Moomoo
Will Expanded Coverage of Guardant’s Shield Test Reshape UnitedHealth Group’s (UNH) Preventive Care Narrative? - Yahoo Finance
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $165 - Moomoo
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout | AI
Press Release: Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
Cancer Blood Screen Company’s SPAC Merger Is Delayed by Test’s Results - Barron's
Guardant Health sets July 30 call for Q2 2026 results - Stock Titan
Guardant Health (GH) Stock May Be Fully Priced As Shield Coverage Expands - simplywall.st
GH Maintained by Morgan Stanley -- Price Target Raised to $175 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $161.13, Implies 3% Upside - TradingView
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $175 - Moomoo
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 - Yahoo Finance
Guardant Health Slides as Investors Appear to Take Profits After Recent Rally - Moomoo
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):